Commercialization of a cell-manufacturing process optimization service - Lab2Market (Market assessment)

基于细胞的疗法有望彻底改变世界各地的医疗保健。有望治愈慢性疾病，并完全修复受损的组织和器官，对这些治疗的需求将是巨大的-成本也是如此。虽然最初的几种基于细胞的治疗方法已经进入加拿大医疗保健市场，但巨大的价格标签成为医生，专利和政府接受治疗的瓶颈。在某些情况下，单是细胞制造的商品成本估计就在每名患者每剂数万甚至数十万美元。如果经济上不可行，有效的治愈性治疗可能就不会出现。细胞制造的成本必须降低，才能使细胞疗法变得可行。 在过去的几年里，我们设计了一个生物医学平台，集成了可扩展的细胞培养，先进的统计方法和机器学习以及机器人系统，以系统地优化细胞制造过程，使其更便宜，更快，更强大。我们的二级市场研究表明，对电池制造过程优化服务的需求非常强烈。通过实验室2市场计划进行市场评估所需的资金将使我们能够专注于主要市场研究，以确认，扩展或反驳我们的营销计划假设，并为我们的平台商业化制定详细的战略。

Cell-based therapies are poised to revolutionize healthcare around the world. Promising to cure chronic diseases, and fully repair damaged tissues and organs, demand for these treatments will be tremendous - as will the costs. While the first few cell-based treatments have entered Canadian health care market, the massive price tag serves as a bottleneck for the uptake of treatments by doctors, patents and the government. In some cases, the cost-of-goods alone for cell manufacturing is estimated to be in the tens and even hundreds of thousands of dollars per dose per patient. Effective, curative treatments may not see the light of day if they are not economically viable. The cost of cell manufacturing must come down to make cell therapies accessible. Over the past several years, we have engineered a biomedical platform integrating scalable cell culture, advanced statistical methods and Machine Learning, and robotic systems to systematically optimize cell manufacturing processes, making them cheaper, faster, and more robust. Our secondary market research indicates a strong need for the cell manufacturing process optimization service. The requested funds for a Market Assessment via a Lab 2 Market program will allow us to focus on primary market research to confirm, expand, or disprove our marketing plan assumptions, and to develop a detailed strategy for the commercialization of our platform.